Literature DB >> 15281085

Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.

Masanori Kanatani1, Toshitsugu Sugimoto, Hideaki Sowa, Tatsuya Kobayashi, Michiko Kanzawa, Kazuo Chihara.   

Abstract

It is well known that thyroid hormone excess causes bone loss. However, the precise mechanism of bone loss by thyroid hormone still remains unclear. When T(3) was added to unfractionated bone cells after degeneration of pre-existent osteoclasts, T(3) (1 pM-100 nM) dose-dependently stimulated osteoclast-like cell formation, irrespective of the presence of indomethacin and IL-6 Ab. T(3) increased the expression of osteoprotegerin (OPG) messenger RNA (mRNA), but not of receptor activator of nuclear factor kappaB ligand (RANKL) in unfractionated bone cells, suggesting that the stimulatory effect of T(3) on osteoclast formation was not mediated by the RANKL/OPG system. We next examined the direct effect of T(3) on osteoclast precursors in the absence of osteoblasts, using hemopoietic blast cells derived from spleen cells. T(3) (1 pM-100 nM) dose-dependently stimulated osteoclast-like cell formation from osteoclast precursors. OPG did not inhibit T(3)-induced osteoclast formation from osteoclast precursor cells. The polymerase chain reaction (PCR) product corresponding in size to the mouse T(3) receptor alpha1 cDNA was detected in osteoclast precursors from mouse hemopoietic blast cells as well as mouse heart and mouse osteoblastic cell line MC3T3-E1 cells, suggesting that T(3) directly stimulated osteoclast-like cell formation from osteoclast precursors in the absence of osteoblasts. Further, T(3) increased the expression of c-Fos mRNA at 15 min and 24 h and Fra-1 mRNA at 2 and 6 h in osteoclast precursors. Consistent with the increased expression of c-Fos mRNA observed by RT-PCR, the activation of c-Fos occurred in osteoclast precursor cells stimulated by T(3), while the activation of neither NF-kappaB nor MAPKs was observed by immunoblot analysis. Antisense oligodeoxynucleotides (as-ODN) complementary to c-Fos mRNA at 1 microM significantly inhibited T(3)-induced osteoclast-like cell formation from osteoclast precursors in the absence of stromal cells while sense-ODN did not affect T(3)-induced osteoclast-like cell formation. These results indicate that T(3) directly stimulates osteoclast differentiation at least in part by up-regulation of c-fos protein in osteoclast precursor cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15281085     DOI: 10.1002/jcp.20041

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  12 in total

Review 1.  Thyroid hormone actions in cartilage and bone.

Authors:  Graham R Williams
Journal:  Eur Thyroid J       Date:  2012-12-19

2.  Response of trabecular bone, thyroid C and follicular cells to synthetic salmon calcitonin in middle-aged orchidectomized male rats.

Authors:  Branko Filipović; Branka Šošić-Jurjević; Vladimir Ajdžanović; Jasmina Živanović; Nataša Ristić; Svetlana Trifunović; Verica Milošević
Journal:  J Anat       Date:  2017-02-20       Impact factor: 2.610

3.  [The Ludwigshafen Osteoporosis Screening Questionnaire (LOS Questionnaire): result of the evaluation of anamnestic risk factors in osteoporosis diagnostics].

Authors:  C Wölfl; C Takur; A A Moghaddam; G Zimmermann; M Hitzler; H Schmidt-Gayk; B Höner; P A Grützner; L Kolios
Journal:  Unfallchirurg       Date:  2013-02       Impact factor: 1.000

Review 4.  Role of thyroid hormones in craniofacial development.

Authors:  Victoria D Leitch; J H Duncan Bassett; Graham R Williams
Journal:  Nat Rev Endocrinol       Date:  2020-01-23       Impact factor: 43.330

Review 5.  Role of Thyroid Hormones in Skeletal Development and Bone Maintenance.

Authors:  J H Duncan Bassett; Graham R Williams
Journal:  Endocr Rev       Date:  2016-02-10       Impact factor: 19.871

6.  Anamnestic risk factor questionnaire as reliable diagnostic instrument for osteoporosis (reduced bone morphogenic density).

Authors:  Leila Kolios; Caner Takur; Arash Moghaddam; Mirjam Hitzler; Heinrich Schmidt-Gayk; Arnold J Suda; Bernd Höner; Paul A Grützner; Christoph Wölfl
Journal:  BMC Musculoskelet Disord       Date:  2011-08-17       Impact factor: 2.362

7.  Do premenopausal hypothyroid women on levothyroxine therapy need bone status monitoring?

Authors:  Ruby P Babu; Alap Christy; Anupama Hegde; Poornima Manjrekar; Vivian D'Souza
Journal:  Clin Med Insights Womens Health       Date:  2015-03-15

8.  Thyroid Mediation of the Isoflavone Effects on Osteoporotic Bone: The Endocrine Interference With a Beneficial Outcome.

Authors:  Branka Šošić-Jurjević; Vladimir Ajdžanović; Branko Filipović; Walter Severs; Verica Milošević
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-11       Impact factor: 5.555

9.  Bone Indices in Thyroidectomized Patients on Long-Term Substitution Therapy with Levothyroxine Assessed by DXA and HR-pQCT.

Authors:  Emil Moser; Tanja Sikjaer; Leif Mosekilde; Lars Rejnmark
Journal:  J Thyroid Res       Date:  2015-07-13

10.  Treatment of subclinical hypothyroidism does not affect bone mass as determined by dual-energy X-ray absorptiometry, peripheral quantitative computed tomography and quantitative bone ultrasound in Spanish women.

Authors:  Juan D Pedrera-Zamorano; Raul Roncero-Martin; Julian F Calderon-Garcia; Mercedes Santos-Vivas; Vicente Vera; Mariana Martínez-Alvárez; Purificación Rey-Sanchez
Journal:  Arch Med Sci       Date:  2015-10-12       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.